Literature DB >> 23167348

Survival of patients with lung cancer, Yazd, Iran.

Shokouh Taghipour Zahir1, Maryammosadate Mirtalebi.   

Abstract

BACKGROUND: Lung carcinoma is the leading cause of cancer mortality worldwide. Although the 5-year survival rate nearly tripled from 5-15% over the last 25 years, the estimated number of deaths still exceeds 1.3 million annually. The overall 5-year survival of lung cancer is only 10% in Europe and 15% in the United States. The aim of the current study was to determine the long-term survival and the effect of certain prognostic factors on survival of patients with lung cancer in Yazd city, Iran.
METHODS: In this cross-sectional descriptive study, we retrospectively reviewed hospital records and follow-up data of 148 patients with histological proven lung cancer using the cancer data registered between 1998 and 2005 in the pathology department of Shahid Sadoughi educational hospital, Yazd, Iran. Data were extracted from patient documents that included sex, age, clinical manifestations, histopathological report of the tumor and type of treatment given.
RESULTS: Overall survival time in all patients was 8.5 months after diagnosis and there was no significant difference in survival according to sex (p=0.958). Histological analysis revealed that squamous cell carcinoma was the most common histologic type (35%). Kaplan-Meier statistical methods estimated the average survival time for SCC to be better (22.6 months) in comparison with the other types of histology (all of them below 10 months). There was a trend towards significance between type of histology and duration of survival (p=0.08).
CONCLUSION: It is reasonable to expect that early lung cancer detection, and appropriated treatment, may improve surgical morbidity and mortality. Low survival of lung cancer in our center patients show our shortages in screening programs for early diagnosis. Designing studies with larger sample size that take some other variables like staging of patients is now necessary.

Entities:  

Mesh:

Year:  2012        PMID: 23167348     DOI: 10.7314/apjcp.2012.13.9.4387

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  CUGBP1 promotes cell proliferation and suppresses apoptosis via down-regulating C/EBPα in human non-small cell lung cancers.

Authors:  Haijiao Lu; Zhuang Yu; Shihai Liu; Lianhua Cui; Xiaozheng Chen; Ruyong Yao
Journal:  Med Oncol       Date:  2015-02-21       Impact factor: 3.064

2.  XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.

Authors:  Chong Li; Xu Zheng; Yanyan Han; Yan Lv; Fu Lan; Jie Zhao
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

3.  Exercise Training in Patients With Non-Small Cell Lung Cancer During In-Hospital Chemotherapy Treatment: A RANDOMIZED CONTROLLED TRIAL.

Authors:  Anna Rutkowska; Dariusz Jastrzebski; Sebastian Rutkowski; Aleksandra Żebrowska; Arkadiusz Stanula; Jan Szczegielniak; Dariusz Ziora; Richard Casaburi
Journal:  J Cardiopulm Rehabil Prev       Date:  2019-03       Impact factor: 2.081

Review 4.  A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries.

Authors:  Bagher Farhood; Behzad Raei; Reza Malekzadeh; Maryam Shirvani; Masoud Najafi; Tohid Mortezazadeh
Journal:  Contemp Oncol (Pozn)       Date:  2019-04-05

5.  Epidemiology of lung cancer in northeast of Iran: A 25-year study of 939 patients.

Authors:  Mahta Salehi; Maryam Salehi; Soodabeh Shahidsales; Golboo Goshayeshi; Maryam Emadzadeh; Mahdi Seilanian Toosi; Seyed-Amir Aledavood; Seyede Samaneh Hoseini; Pardis Shojaei
Journal:  Med J Islam Repub Iran       Date:  2020-03-07

6.  Detecting Important Risk Factors of Survival Time of Lung Cancer Patients Using Censored Quintile Regression.

Authors:  Payam Amini; Malek Abazari; Behnaz Alafchi
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

7.  Long non-coding RNA LSAMP-1 is down-regulated in non-small cell lung cancer and predicts a poor prognosis.

Authors:  Wei Gong; Yinyan Li; Jianfeng Xian; Lei Yang; Yuanyuan Wang; Xin Zhang; Yifeng Zhou; Xinhua Wang; Guibin Qiao; Cuiyi Chen; Soham Datta; Xincheng Gao; Jiachun Lu; Fuman Qiu
Journal:  Cancer Cell Int       Date:  2022-05-06       Impact factor: 6.429

8.  Lung Cancer Prevalence in Iran by Histologic Subtypes.

Authors:  Hossein Molavi Vardanjani; Masoud Zeinali; Samera Radmerikhi; Maryam Hadipour
Journal:  Adv Biomed Res       Date:  2017-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.